Paris, France – Global medical aesthetics company Cynosure Lutronic showcased its newly certified Mosaic 3D laser platform at IMCAS Paris 2026, the world’s largest aesthetic and anti-aging medical congress, held in Paris, France. The launch marks a significant step for the South Korean firm as it expands its reach in the European market and introduces advanced fractional laser technology to practitioners.
The IMCAS (International Master Course on Aging Science) conference is a key event for the medical aesthetics industry, attracting dermatologists, plastic surgeons, and industry leaders from around the globe. Cynosure Lutronic’s presence at IMCAS Paris 2026 underscores the growing influence of K-beauty and Korean medical technology in the international aesthetics landscape. The company’s focus on innovation and its commitment to meeting stringent regulatory standards are central to its strategy, particularly within the European Union.
Mosaic 3D Receives EU MDR Certification
Prior to its official launch at IMCAS, the Mosaic 3D platform secured EU Medical Device Regulation (MDR) certification, a critical requirement for medical device sales within the European Economic Area. According to koreabiomed.com, this certification demonstrates Cynosure Lutronic’s adherence to the highest safety and performance standards. The EU MDR is a rigorous regulatory framework designed to ensure the safety and efficacy of medical devices, and obtaining this certification is a significant achievement for the company.
CE Mark Approval for Expanded Market Access
In addition to the EU MDR certification, Cynosure Lutronic has also secured a CE Mark for the Mosaic 3D platform. Yahoo Finance reports that the CE Mark signifies that the device meets EU safety, health, and environmental protection requirements, allowing for broader distribution and sales across Europe. This approval is crucial for Cynosure Lutronic as it seeks to establish a stronger foothold in the competitive European medical aesthetics market.
K-Medical Aesthetics Leading Innovation
The launch of Mosaic 3D at IMCAS Paris 2026 is part of a broader trend of Korean medical aesthetics companies gaining prominence on the global stage. Medical Aesthetic News highlights this growing influence, noting that K-beauty and Korean medical technology are increasingly recognized for their innovation and quality. The Mosaic 3D platform, with its advanced fractional laser technology, exemplifies this trend.
The Mosaic 3D platform utilizes a unique 3D matrix of microscopic laser beams to create controlled micro-injuries in the skin. This process stimulates the body’s natural healing response, leading to collagen remodeling and improved skin texture. The device is designed to address a range of aesthetic concerns, including wrinkles, scars, and uneven skin tone. The platform’s precision and customizable settings allow practitioners to tailor treatments to individual patient needs.
What to Expect Next
With EU MDR certification and CE Mark approval secured, Cynosure Lutronic is poised to expand the availability of the Mosaic 3D platform throughout Europe. The company will likely focus on building relationships with key opinion leaders and providing comprehensive training to practitioners to ensure optimal treatment outcomes. The success of the Mosaic 3D launch will be a key indicator of Cynosure Lutronic’s ability to compete effectively in the rapidly evolving medical aesthetics market. Further announcements regarding distribution partnerships and clinical studies are anticipated in the coming months.
Have your say! What are your thoughts on the growing influence of K-beauty technology in the medical aesthetics industry? Share your comments below.
